Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 in Primary Biliary Cholangitis (PBC)
NCT07282353Phase 3Recruiting
- Sponsor
- Cascade Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of linafexor in primary biliary cholangitis (PBC), sponsored by Cascade Pharmaceuticals. Started Dec 2025; status: recruiting.
02
Drugs
linafexor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT07282353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282353.